Relapsing-Remitting Multiple Sclerosis (MS) Market Research Report Information By Treatment (Immunomodulating Drugs, Nrf2 Activators, Interferons, Others), By Route of Administration (Oral, Intravenous) and By End-User (Hospitals, Clinics, Others) – Forecast to 2032

Relapsing-Remitting Multiple Sclerosis Market Overview

The Relapsing-Remitting Multiple Sclerosis market is expected to reach USD 5.8 Billion by 2032 at CAGR 3.1% during the forecast period 2023-2032.

Multiple sclerosis, specifically relapsing-remitting multiple sclerosis, is a type of disease. It will be the most frequent kind of multiple sclerosis, contributing to approximately 85 percent of all new MS diagnoses in the United States. People who have RRMS have relapses of MS, with recovery periods happening in the intervening time. A chronic, degenerative disorder of the central nervous system wherein the human immune system assaults myelin, the insulating covering surrounding nerve fibers, multiple sclerosis is defined as follows: An inflammatory response in the nerves is caused by myelin damage, making it harder for your mind to communicate with the entire body.

In the last few decades, there has also been a significant amount of study into the Relapsing-Remitting Multiple Sclerosis Market, which is having an impact on the worldwide market's development. A large number of businesses are now undergoing clinical studies for their medication concepts, which, if authorized, would accelerate the pace of success in the market. Global MS medication sales have recently been propelled by a combination of factors, including a large unmet medical demand for treatments and an active R&D pathway. As a result, the worldwide MS medications market has grown as a result of an increase in MS research and development.

This report contains all the global market of Relapsing-Remitting Multiple Sclerosis analysis and its strengths. In addition, the report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the global market of Relapsing-Remitting Multiple Sclerosis forecast for 2032 is also included in the report.

April 2024: Immunic, Inc. Today, a biotechnology company that is in the process of developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that the data from its phase 2 EMPhASIS trial of the lead asset, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS), was published online on April 25, 2024 in Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology. As previously reported, vidofludimus calcium exhibited a dose-dependent effect on the suppression of new combined unique active (CUA) magnetic resonance imaging (MRI) as well as gadolinium-enhancing (Gd+) lesions. Additionally, an encouraging initial signal was observed in relation to the reduction of 12-week and 24-week confirmed disability worsening events in comparison to the placebo during the double-blind treatment period. The drug's combined neuroprotective and anti-inflammatory effects are strikingly emphasized by the results. In the interim, we are continuing to enroll patients in our twin phase 3 ENSURE trials for relapsing multiple sclerosis. We anticipate reporting an interim futility analysis in late 2024, with the top-line outcome of the first of the ENSURE trials expected in the second quarter of 2026. The first cohort of the multicenter, double-blind, randomized, placebo-controlled phase 2 EMPhASIS trial demonstrated that vidofludimus calcium, an orally available first-in-class nuclear receptor related 1 (Nurr1) activator and next-generation dihydroorotate dehydrogenase (DHODH) inhibitor, suppressed MRI disease activity in patients with RRMS compared to placebo. The drug achieved all primary and key secondary endpoints with high statistical significance.

In February 2024, Roche Pharma India introduced a drug to treat Multiple Sclerosis (MS), thereby broadening its neurology portfolio to address the unmet requirements of patients affected by the disease. The company has introduced Ocrevus (Ocrelizumab), the first and only approved disease-modifying therapy for both Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Remitting Multiple Sclerosis (RRMS). Ocrevus patients exhibit the highest persistence and superior adherence to treatment due to its twice-yearly (once every six months) administration, which is preferred by the majority of patients in comparison to more frequent (monthly) injections. Ocrevus instills new hope in individuals who are struggling with this extremely challenging neurological condition, as it boasts a long-term safety record, streamlined administration, and formidable efficacy. Multiple sclerosis is a prevalent cause of non-traumatic disability in younger adults, as the majority of individuals are diagnosed between the ages of 20 and 40.

Covid 19 Analysis

COVID-19 has resulted in a financial and healthcare disaster in the United States. It is expected that industrialized nations would endure a downturn as a consequence of the COVID-19 epidemic, which has stressed the global medical system. There has been a 50 to 70 percent decline in healthcare income since March due to the epidemic. One or two smaller medical facilities have been compelled to close their doors. There have also been delays in elective surgeries due to social isolation and municipal curfews. The tourism industry has been interrupted by visa denials, which might harm expanding the relapsing-remitting MS sector.

Relapsing-Remitting Multiple Sclerosis Market Dynamic          

Drivers

The worldwide relapsing-remitting multiple sclerosis market is growing because of an elderly society. One in six individuals in the globe will be 65 years and older by the year 2050, as per new research. An estimated one in every four persons in Europe and North America would be impacted. This age range had already overtaken the number of kids under five in 2018. Due to an increasingly aging population, relapsing-remitting MS drugs are predicted to have an upsurge in demand.

Opportunities

According to recent research, monoclonal antibodies are progressively being used in the diagnosis of RRMS. A large number of clinical studies are being conducted on innovative medications that are based on antibodies. In order to address this illness, there is a rise in the need for immunosuppressive medications.

Restraints

The patent expiration of essential medications, on the other hand, is a significant limitation on the worldwide market for MS treatments. Moreover, the worldwide market outlook of Relapsing-Remitting Multiple Sclerosis is hampered by rigorous regulatory restrictions that limit its expansion.

Challenges

Owing to greater government involvement and the availability of a range of therapeutic choices for multiple sclerosis, the expense of medications continues to be a significant barrier to the market's expansion. 

Cumulative Growth Analysis

The increasing number of agreements entered into by major companies in the business is encouraging. Examples include TG Therapeutics, Inc. entering into a settlement with the United States Food and Drug Administration on the Special Protocol Assessment (SPA) of phase iii clinical research for TG-1101, an anti-D20 monoclonal antibody being studied in the management of relapse types of MS.

Expanding the number of medications in development pipelines. Antisense Pharmaceuticals confirmed the continuation of its Phase 2b clinical studies in October 2017, after the US Food and Therapeutic Administration removed the regulatory holds on the company's drug candidate ATL1102. It is intended to treat relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis.

Value Chain Analysis

According to the reports, the global market of Relapsing-Remitting Multiple Sclerosis is segmented based on the treatment, route of administration, end-users, and regions. Immunomodulatory drugs inhibit an enzyme in the mitochondrial that creates pyrimidines to provide anti-inflammatory actions. Teriflunomide, for example, is used to treat relapsing types of multiple sclerosis. Nrf2 Activators is anticipated to witness the fastest Market growth of Relapsing-Remitting Multiple Sclerosis category because of the higher survival rate of cancer patients. Studies reveal that Interferons reduce the risk of MS relapses by an average of 18 to 38 percent. Dimethyl fumarate is one of the therapeutic goods in the other sector. As so many medications need to be delivered orally, this is projected to be the most significant market sector. Because of increasing research in this subject, the intravenous segment is likely to develop the quickest.

Segmentation Overview

The market is segmented based on the treatment, route of administration, end-users, and regions. The global Market trends of Relapsing-Remitting Multiple Sclerosis are expected to witness decent growth during the forecast period.

Relapsing-Remitting Multiple Sclerosis Treatment Insights

The application market is segmented into Immunomodulating Drugs, Nrf2 Activators, Interferons, and Others.

Relapsing-Remitting Multiple Sclerosis Route of Administration Insights

Based on the propulsion types, the market is segmented into Oral and Intravenous

Relapsing-Remitting Multiple Sclerosis Regional Insights

According to the reports, based on region, the global Relapsing-Remitting Multiple Sclerosis (MS) Market is divided into America, Europe, Asia Pacific, and the middle east and Africa. The Americas is expected to be the most significant regional market. Research facilities in nations such as the United States and Canada are well. Furthermore, the key enterprises that have been developed in this location have superior manufacturing skills. Consequently, the relapsing-remitting MS industry in this area is expected to rise in the coming years. Furthermore, the growing number of patients is having an impact on development. For example, over 400,000 individuals in the United States have multiple sclerosis.

Research funding increased occurrence rates of multiple sclerosis, and improvements in the healthcare system are all predicted to contribute to expanding the relapsing-remitting MS market within the European area. For example, the maximum count of MS sufferers in Germany is around 200,000.

According to Relapsing-Remitting Multiple Sclerosis (MS) Market forecasts, the Asia-Pacific area is anticipated to witness the fastest region in the Relapsing-Remitting Multiple Sclerosis Market value. There has been an uptick in the population of persons suffering from chronic ailments in this area. Each week, around ten Australians are afflicted with multiple sclerosis. It is anticipated that a significant increase in the number of people who have multiple sclerosis would fuel growth in the Relapsing-Remitting Multiple Sclerosis Market share in the area in the coming years.

Competitive landscape

The rising number of efforts by both governments and enterprises is helping to propel the development of the Relapsing-Remitting Multiple Sclerosis Market. According to the forecast, the growing percentage of product releases by leading competitors in the field is expected to be a significant supporting element to the rise in the coming years.

Relapsing-Remitting Multiple Sclerosis (MS) Market Major Key Players

• Biogen (US)


• Eisai Co., Ltd (Japan)


• Glenmark Pharmaceuticals (India)


• Merck KGaA (US)


• Novartis AG (Switzerland)


• Sanofi Genzyme (US)


• Teva Pharmaceutical Industries Ltd (Israel)

Recent Developments

• Ocrevus was introduced by F. Hoffman-La Roche Ltd. in 2017, and it quickly established itself as one of the most profitable drugs on the market.

Relapsing-Remitting Multiple Sclerosis Market Segmentation

Relapsing-Remitting Multiple Treatment Outlook

• Immunomodulating Drugs


• NrF2 Activators


• Interferons


• Others

Relapsing-Remitting Multiple Route of Administration Outlook

• Oral


• Intravenous

Relapsing-Remitting Multiple Sclerosis End User Outlook

• Hospitals


• Clinics


• Others

Relapsing-Remitting Multiple Sclerosis Region Outlook

• North America




• U.S.


• Canada


• Mexico




• Europe




• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe




• Asia-Pacific




• China


• Japan


• India


• South Korea


• Australia


• Rest of Asia-Pacific




• LAMEA




• Brazil


• Saudi Arabia


• South Africa


• Rest of LAMEA

Report Attribute/Metric	Details
Market Size	5.8 Billion
CAGR	3.1% (2023 - 2032)
Base Year	2019
Forecast Period	2023-2032
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Treatment, Route of Administration, End-User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Glenmark Pharmaceuticals (India), Eisai Co., Ltd (Japan), Biogen (US), Merck KGaA (US), Sanofi Genzyme (US), Novartis AG (Switzerland), and Teva Pharmaceutical Industries Ltd (Israel).
Key Market Opportunities	·  Increasing product launches·  Rising need for accurate diagnosis
Key Market Drivers	·  Increasing research initiatives·  Rising need for treatment of relapsing-remitting MS·  Growing awareness regarding the severity of this form of MS